Table 4. Comparison of indices in heterozygous carriers and normal controls.

Indices	Heterozygous carriers (n=20)	Normal controls (n=40)	P
C12	0.06±0.051	0.07±0.021	0.29
C14	0.15±0.061	0.17±0.041	0.23
C16	2.62±0.761	2.59±0.571	0.90
C18	0.81±0.191	0.79±0.171	0.65
C16:1	0.17±0.081	0.18±0.051	0.81
C18:1	1.45±0.621	1.40±0.301	0.76
C18:2	0.32±0.181	0.23±0.081	0.05
C16:1-OH	0.04±0.011	0.03±0.011	0.06
(C16 + C18)/C0	0.13±0.05	0.15±0.04	0.24
(C16 + C18:1)/C2	0.27±0.08	0.18±0.04	<0.01
C14/C3	0.09±0.04	0.09±0.03	0.89
C16/C2	0.17±0.06	0.12±0.03	<0.01
C16/C3	1.66±0.66	1.43±0.42	0.17
C18/C3	0.51±0.17	0.44±0.14	0.08
C16:1/C3	0.11±0.06	0.10±0.03	0.35
C16:1-OH/C3	0.02±0.007	0.02±0.005	0.01

Heterozygous carriers: only the c.199-10T>G mutant of the SLC25A20 gene was present without any pathogenic and likely pathogenic mutations and mutations of uncertain significance in the CPT2 gene. Normal controls: absence of pathogenic and likely pathogenic mutations and mutations of uncertain significance in SLC25A20 and CPT2 gene. Data are presented as mean values ± standard deviation. ¹, the unit is μmol/L. C12, dodecanoylcarnitine; C14, tetradecanoylcarnitine; C16, palmitoylcarnitine; C18, stearylcarnitine; C16:1, hexadecenoylcarnitine; C18:1, octadecenoylcarnitine; C18:2, linoleylcarnitine; C16:1-OH, hydroxy hexadecenoylcarnitine; C0, free carnitine; C2, acetylcarnitine; C3, propionylcarnitine.